AR106227A1 - COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) - Google Patents

COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)

Info

Publication number
AR106227A1
AR106227A1 ARP160103006A ARP160103006A AR106227A1 AR 106227 A1 AR106227 A1 AR 106227A1 AR P160103006 A ARP160103006 A AR P160103006A AR P160103006 A ARP160103006 A AR P160103006A AR 106227 A1 AR106227 A1 AR 106227A1
Authority
AR
Argentina
Prior art keywords
lpa
gene
apo
inhibit
compositions
Prior art date
Application number
ARP160103006A
Other languages
Spanish (es)
Inventor
Almeida Aaron
Li Zhen
Pei Tao
S Trubetskoy Vladimir
H Wakefield Darren
J Almeida Lauren
L Lewis David
B Rozema David
Kanner Steven
Melquist Stacey
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of AR106227A1 publication Critical patent/AR106227A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen los agentes de interferencia de ARN (ARNi) y los conjugados de los agentes ARNi para inhibir la expresión del gen LPA (apo(a)). También se describen composiciones farmacéuticas que comprenden uno o más agentes de ARNi de LPA opcionalmente con uno o más agentes terapéuticos. La entrega de los agentes de ARNi de LPA descritos a las células hepáticas in vivo proporciona la inhibición de la expresión del gen LPA y el tratamiento de enfermedades cardiovasculares y cardiovasculares relacionadas.RNA interference agents (RNAi) and the conjugates of RNAi agents to inhibit the expression of the LPA gene (apo (a)) are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more therapeutic agents are also described. The delivery of the described LPA RNAi agents to liver cells in vivo provides inhibition of LPA gene expression and the treatment of related cardiovascular and cardiovascular diseases.

ARP160103006A 2015-10-01 2016-09-30 COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) AR106227A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
AR106227A1 true AR106227A1 (en) 2017-12-27

Family

ID=60923936

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160103006A AR106227A1 (en) 2015-10-01 2016-09-30 COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)
ARP210100996A AR121850A2 (en) 2015-10-01 2021-04-15 LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210100996A AR121850A2 (en) 2015-10-01 2021-04-15 LPA RNA INTERFERENCE AGENT (RNAi), USE OF SAID AGENT AND METHOD FOR INHIBITING LPA EXPRESSION

Country Status (1)

Country Link
AR (2) AR106227A1 (en)

Also Published As

Publication number Publication date
AR121850A2 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
CO2018003678A2 (en) Compositions and methods to inhibit lpa gene expression
ECSP20017905A (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
DOP2019000005A (en) 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2
CO2020001740A2 (en) Iarn agents and compositions to inhibit the expression of angiopoietin type 3 (angptl3) and methods of use
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
GT201700167A (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER.
UY37565A (en) IARN ALFA-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING IARN AAT AGENTS AND METHODS OF USE
CR20160237A (en) DERIVATIVES OF CARBOXAMIDE AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
UY37098A (en) ROR-GAMMA MODULATORS
DOP2012000257A (en) DERIVATIVES OF THE ACID 1-AMINO-2-CICLOPROPILETILBORONICO
EA201692318A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
ECSP20000655A (en) IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENaC AND METHODS OF USE
CO2018002198A2 (en) Pharmaceutical compositions comprising an oligomeric compound to modulate the expression of apolipoprotein (a)
AR106227A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA)
DOP2014000221A (en) METHODS TO TREAT CANCER USING PI3K INHIBITOR AND MEK INHIBITOR
AR113014A1 (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
AR113454A1 (en) IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1
AR113254A1 (en) IRNA AGENTS AND COMPOSITIONS TO INHIBIT THE EXPRESSION OF ANGIOPOYETIN TYPE 3 (ANGPTL3) AND METHODS OF USE
AR112754A1 (en) IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF a-ENaC AND METHODS OF USE
AR105611A1 (en) RNAi THERAPY FOR HEPATITIS B VIRUS INFECTION
AR090580A1 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
CU20120052A7 (en) PIRAZOL DERIVATIVES THAT MODULATE ESTEAROIL-COA-DESATURASA
AR096390A1 (en) COMPOSITIONS OF ARNi DE SERPINA1 AND ITS METHODS OF USE